{"schema_version":"secwatch.filing_event.v1","accession":"0001174947-23-000616","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.346808+00:00","generated_at":"2026-06-16T14:36:18.429424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED Q1 sales $295.5M (+21.9% YoY); raises FY 2023 revenue and EPS guidance","bullets":["Sales $295.5M (+21.9% as reported; +25.1% constant currency); acquisitions contributed ~570 bps growth.","GAAP diluted EPS $0.06 (down 87.2% YoY); adjusted diluted EPS $0.66 (down 5.7% YoY).","Raises FY 2023 revenue guidance to $1.205B-$1.250B from $1.170B-$1.220B.","Raises FY 2023 adjusted EPS guidance to $3.30-$3.50 from $3.20-$3.45.","Adjusted EBITDA $51.2M (17.3% margin) vs $43.7M (18.0% margin) in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001174947-23-000616","json":"https://secwatch.observer/filing/0001174947-23-000616.json","markdown":"https://secwatch.observer/filing/0001174947-23-000616.md","text":"https://secwatch.observer/filing/0001174947-23-000616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000616/0001174947-23-000616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000616/form8k-30039_cnmd.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T14:36:18.429424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b03cb40d9d2a3e698472ad2a619920533edf0334","claim":"CONMED Corp reported the full year 2023 results: revenue between $1.205 billion and $1.250 billion, EPS in the range of $3.30 to $3.50. Guidance raised.","evidence_excerpt":"Based on the first quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.205 billion and $1.250 billion, compared to its prior guidance of between $1.170 billion and $1.220 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000616/0001174947-23-000616-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023"},{"label":"Revenue","value":"between $1.205 billion and $1.250 billion"},{"label":"EPS","value":"in the range of $3.30 to $3.50"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f2ab1706be1e3b01f3c342bbf93ed21212c7d7e3","claim":"CONMED Corp reported the first quarter ended March 31, 2023 results: revenue $295.5 million, EPS $0.06.","evidence_excerpt":"Florida, April 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights · Sales of $295.5 million increased 21.9% year over year as reported and 25.1% in constant currency. Acquisitions contributed approximately 570 basis points of growth. · Domestic revenue increased 25.4%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000616/0001174947-23-000616-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$295.5 million"},{"label":"EPS","value":"$0.06"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}